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ABSTRACT
Purpose: Survival among patients with adenocarcinoma pancreatic cancer (PDCA)  
is  highly variable, which ranges from 0% to 20% at 5 years. Such a wide range is 
due to tumor size and stage, as well other patients’ characteristics. We analyzed 
alterations in the metabolomic profile, of PDCA patients, which are potentially 
predictive of patient's one-year mortality.
Experimental design: A targeted metabolomic assay was conducted on serum 
samples of patients diagnosed with pancreatic cancer. Statistical analyses were 
performed only for those 27 patients with information on vital status at follow-up 
and baseline clinical features. Random Forest analysis was performed to identify all 
metabolites and clinical variables with the best capability to predict patient’s mortality 
risk at one year. Regression coefficients were estimated from multivariable Weibull 
survival model, which included the most associated metabolites. Such coefficients 
were used as weights to build a metabolite risk score (MRS) which ranged from 0 
(lowest mortality risk) to 1 (highest mortality risk). The stability of these weights 
were evaluated performing 10,000 bootstrap resamplings.
Results: MRS was built as a weighted linear combination of the following five 
metabolites: Valine (HR = 0.62, 95%CI: 0.11–1.71 for each standard deviation (SD) of 
98.57), Sphingomyeline C24:1 (HR = 2.66, 95%CI: 1.30–21.09, for each SD of 20.67), 
Lysine (HR = 0.36, 95%CI: 0.03–0.77, for each SD of 51.73), Tripentadecanoate TG15 
(HR = 0.25, 95%CI: 0.01–0.82, for each SD of 2.88) and Symmetric dimethylarginine 
(HR = 2.24, 95%CI: 1.28–103.08, for each SD of 0.62), achieving a very high 
discrimination ability (survival c-statistic of 0.855, 95%CI: 0.816–0.894). Such 
association was still present even after adjusting for the most associated clinical 
variables (confounders).
Conclusions: The mass spectrometry-based metabolomic profiling of serum 
represents a valid tool for discovering novel candidate biomarkers with prognostic 
ability to predict one-year  mortality risk in patients with pancreatic adenocarcinoma.
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INTRODUCTION
Pancreatic cancer (PC) is a highly aggressive and 
chemoresistant cancer [1].
Recently, scientists are struggling to find out a 
biomarker which may highlight the prediction of an 
uprising PC. 
Up to date several clinical serum markers for PC 
were proposed: a) carbohydrate antigen 19-9 (CA 19-
9) which is the most commonly utilized, b) cell surface 
associated mucin (MUC1), c) carcinoembryonic antigen-
related cell adhesion protein molecule 1 (CEACAM1), 
and more recently d) a pyruvate kinase variant (M2-
PK) [2]. However, these markers lack sensitivity and 
specificity, as they are unfrequently elevated in the early 
stage of the cancerogenesis, and may be over-expressed 
also in various inflammatory conditions [2, 3]. On the 
other hand, scientists focused their attention also on 
investigating factors potentially involved into survival 
and/or therapy response. A number of genes were proven 
to be associated with survival and/or therapy outcome 
prediction. For instance, higher DNA methyltransferase 
3B (DNMT3B) mRNA levels predict longer survival 
in PC patients in the presence of non-invasive tumor 
whereas higher DNMT3B mRNA levels were associated 
with a poor prognosis in the presence of invasive tumor 
[4]. Moreover human ribonucleotidereductase (RRM1), 
involved in the homeostasis of nucleotides pools affecting 
cell proliferation, migration and metastasis [5] was found 
to improve survival in gemcitabine-treated patients [6–9]. 
Human equilibrative nucleoside transporter 1 (hENT1) 
a drug transporter together with deoxycytidine kinase 
(DCK), a key enzyme that activates gemcitabine by 
phosphorylation, was also found to be associated with 
acquired resistance to gemcitabine both in vitro [10–12] 
and in vivo [13–17]. As several studies reported conflicting 
results, the finding of a potential biomarker which can 
early predict the uprising of the pancreatic cancer and/or 
the chemotherapy outcome still remain unsolved [18].
Herein we analyzed potential changes in the 
concentration levels of metabolites in serum samples 
of pancreatic cancer patients in order to find possible 
associations between the mutual concentration levels of 
these metabolites and clinical pathological features in a 
selected and well characterized cohort of patients with 
PDAC. Moreover, we built and described a multiple risk 
score (MRS) formula, as a weighted linear combination 
of all those metabolites which strongly predict one-year 
patient’s mortality risk. The implementation of our MRS 
formula may help prioritize the use of available resources 
for targeting aggressive preventive and treatment strategies 
in a subset of very high-risk individuals.
RESULTS
Metabolites concentration levels in PC patients
Concentration value for each metabolite in PC 
patients were reported in Supplementary Table 1 whilst 
our metabolomic analysis was performed and described 
in the twin paper: Di Gangi I, Mazza T, Fontana A, 
Copetti M, Fusilli C, Ippolito A, Mattivi F, Latiano A, 
Andriulli A, Vrhovsek U and Pazienza V. "Metabolomic 
profile in pancreatic cancer patients: a consensus-based 
approach to identify highly discriminating metabolites". 
Oncotarget 2016 IN PRESS. We found that Valine, 
Sphingomyeline C24:1, Lysine, Histidine, Tryptophan, 
Octadecenoylcarnitine, Tripentadecanoate TG15, 
LysoPhosphatidylcholine acyl C20:3, Docosahexaenoic 
Acid, Sphingomyeline C18:1, LysoPhosphatidylcholine 
acyl C20:4, Phosphatidylcholinediacyl C32:0, 
Symmetric dimethylarginine, Glycoursodeoxycholic 
Acid, 1monopalmitoleoyl-rac-GL1, G-LCA, 
LysoPhosphatidylcholine acyl C18:0 were the most 
important predictors of one year mortality risk (as shown 
in Figure 1 reporting from the most to the less important). 
Among metabolites detected in RSF, we found that Valine, 
Sphingomyeline C24:1, Lysine, Tripentadecanoate TG15 
and Symmetric dimethylarginine were selected following 
the stepwise variable selection criterion (achieving a 
AIC of −5.04) and entered into the Weibull multivariable 
survival model. Univariable and multivariable two-order 
fractional polynomial models indicated a linear association 
between such metabolites and one-year mortality risk as 
more informative than any other non-linear association. 
Moreover, no significant improvement in model’s 
goodness of fit was achieved when previous metabolites 
were considered into the RECPAM tree-structured analysis 
both as global and splitting variables. 
Risk estimates for mortality at one-year were 
calculated, for each selected metabolite, by the 
multivariable Weibull model, along with empirical 
bootstrap 95%CI. Estimates were reported for each 
unitary increment in metabolites’ SD: Valine (HR = 0.62, 
95%CI: 0.11–1.71, for each SD of 98.57), Sphingomyeline 
C24:1 (HR = 2.66, 95%CI: 1.30–21.09, for each SD of 
20.67), Lysine (HR = 0.36, 95%CI: 0.03–0.77, for each 
SD of 51.73), Tripentadecanoate TG15 (HR = 0.25, 
95%CI: 0.01–0.82, for each SD of 2.88) and Symmetric 
dimethylarginine (HR = 2.24, 95%CI: 1.28–103.08, for 
each SD of 0.62). 
For sake of completeness, we used patients’ 
clinical information to investigate the major clinical 
predictor of mortality risk at one-year. Therefore, we 
run RSF analysis using clinical variables as candidates 
of each node split of each tree included into the forest. 
We found that lactate dehydrogenase, age, smoking 
habits and alcohol consumption resulted to best 
predict the one-year mortality risk (with a relative 
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variable importance greater than 34%). Moreover, we 
found statistically significant positive correlations 
between the Lactate Dehydrogenase levels and the 
following metabolites: Octadecenoylcarnitine (r = 0.41, 
p = 0.044), Docosahexaenoic Acid (r = 0.45, p = 0.023), 
Symmetric dimethylarginine (r = 0.46, p = 0.022), and 
significant negative correlations with Valine (r = −0.41, 
p = 0.043) and tripentadecanoate TG15 (r = −0.43, 
p = 0.030) levels, among PC patients.
The effect of such metabolites (on one-year 
mortality risk) remained statistically significant 
even after adjusting for age, smoking habits, alcohol 
consumption, disease duration and surgical intervention 
(main confounders) either including them one by one or 
all together into the multivariable Weibull model. Such 
associations retained the statistical significance value, 
even after adjusting for “the most important” clinical 
variables (i.e. Lactate Dehydrogenase, Age, Smoking 
habits, Alcohol consumption).
Development of MRS formula
Finally, we used the parameter estimates from 
the multivariable Weibull model as stabilized weights 
to build MRS. Specifically, we found that λ^ = 1.7376 
and γ^ = 1.0769, represented the scale and the shape 
parameters estimates of the baseline survivor function, 
(from the empty Weibull model) respectively. For each 
metabolite, we subtracted its sample mean (we defined 
it as scaled metabolite). Specifically, the sample mean 
values (µmol/L) were: 249.84 for Valine (Val), 23.93 
for Sphingomyeline C24:1 (SMC24), 200.53 for Lysine 
(Lys), 8.46 for Tripentadecanoate TG15 (TG15), 0.76 for 
Symmetric dimethylarginine (SDMA).
The estimated regression coefficients for scaled 
metabolites (around their sample means) were the 
following ones: −0.005 for Val, 0.047 for SMC24, −0.020 
for Lys, −0.483 for TG15, 1.314 for SDMA. 
Therefore, the final MRS formula is computed as 
follows:
MRS = 1−0.1632exp(−0.005∙Val + 0.047∙SMC24−0.020∙Lys-0.483∙TG15 + 1.314∙SDMA)
MRS provided an estimate of the individual 
prediction probability to have a death occurrence within 
one year of follow-up, depending on the individual 
levels of Val, SMC24, Lys, TG15 and SDMA collected 
at baseline. MRS achieved a high discriminatory power 
(i.e. survival c-statistic of 0.855, 95%CI: 0.816–0.894). 
For sake of completeness, the prognostic ability of 
TNM staging (one of the most important factor in 
determining prognosis and treatment options) alone was 
further evaluated, computing the modified c-statistic for 
censored survival data, using predicted probabilities at 
one-year in a multivariable Weibull model. It resulted 
that TNM achieved the a survival c-statistic of 0.591 
(95%CI: 0.467–0.714), which was significantly lower 
than the c-statistic achieved by MRS only, suggesting 
an evident superiority (p < 0.001) for MRS to assign 
higher mortality risk in patients who will die and lower 
mortality risk in patients who will survive.
Figure 1: Relative importance values of the top variables (from the most to the less important) for the Random Forest 
(100,000 trees) which included metabolites only.
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Figure 2: Identification of patients’ subgroups at different risks for one-year mortality: RECPAM survival tree 
(A) and Kaplan-Meier curves (B) for patients who belonged to low, intermediate and high risk classes for MRS. 
RECPAM analysis identified patient subgroups at different risks for mortality. The tree-growing algorithm modeled hazard ratios after a 
Weibull model. MRS was used as splitting variable and splits are shown between branches, while condition sending patients to left or right 
sibling is on relative branch. Class 3 with lowest mortality was reference category (HR = 1). Circles indicate subgroups of patients. Squares 
indicate patient subgroup RECPAM class. Numbers inside circles and squares represent the number of events (top) and the number of non-
events (bottom), respectively.
Oncotarget8972www.impactjournals.com/oncotarget
Survival analysis
RECPAM method was used to identify optimal 
cut-offs for MRS which defined patients’ subgroups for 
MRS with different mortality risk. The algorithm stopped 
at three subgroups (RECPAM classes), which achieved 
the minimum AIC. The reference class (Class 3) was 
represented by the subgroup with the lowest mortality, and 
all the HRs were estimated with respect to such reference 
class. Patients with MRS ≤ 0.50 represented the reference 
class, whereas patients with MRS > 0.88 represented 
the class with the highest mortality risk (Class 1, 
HR = 30.24, 95% CI: 6.01–152.11, p < 0.001). Patients 
with 0.50 < MRS ≤ 0.88 represented the intermediate risk 
class (Class 2, HR = 4.44, 95% CI: 0.79–24.97, p = 0.091).
RECPAM tree along with Kaplan Maier survival 
curves for each RECPAM class are further reported in 
Figure 2 (A and B). MRS distributions are represented into 
a boxplot (Figure 3) for patients who survived and those 
who did not survive at the end of follow-up time.
DISCUSSION
Recent studies performed in gemcitabine sensitive 
and in chemoresistant pancreatic cell lines by Fujimura 
and colleagues [19], observed significant differences 
in metabolites related to several metabolic pathways 
such as amino acids, nucleotides, energy, cofactors, and 
vitamin pathways. These findings were supportive of the 
experimental hypothesis of characteristic features in the 
metabolome of gemcitabine sensitive and resistant cells and 
corroborated the understanding of resistance mechanisms 
in pancreatic cancer. For instance, the altered concentration 
of arginine reported by Bathe [20] may be crucial for the 
increase of eNOS levels and NO production which in turn 
triggers hCHOP-C/EBPa complex formation and reduces 
hENT1 expression [21]. The latter plays an important role 
in predicting clinical outcomes in PDAC [17]. Decreased 
hENT1 levels may also be triggered to a high glucose 
concentration [22, 23], which were found to be altered in 
pancreatic cancer patients’ urine and serum by Napoli et 
al. [24], Davis et al. [25], and Bathe et al. [20]. Creatine, 
creatinine, aspartate, and citrulline are representative 
Figure 3: Boxplot of MRS for patients who survived and those who did not survive, separately.
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metabolites related to urea cycle and are involved in the 
production of nitric oxide (NO). This pathway is related to 
glutamate and proline metabolisms, regulating bioenergetics 
and redox status [26]. Most cancer cells demonstrate an 
increase in glucose uptake, a higher rate of glycolysis, 
and an increase in lactate secretion despite the presence of 
oxygen, a phenomenon known as the Warburg effect [27].
Here we report the analysis of potential changes 
in the concentration of metabolites in serum samples 
of pancreatic cancer patients in order to find possible 
associations between the mutual concentration of 
these metabolites and clinical pathological features 
in a selected and well characterized cohort of patients 
with PDAC. Moreover, among patients with pancreatic 
adenocarcinoma, we identified all those metabolites 
which might be potentially predictive of patient’s one-
year mortality, with the building of a Metabolites Risk 
Score (MRS). Our method consisted in three steps: 
preprocessing, selection and classification and it can be 
adapted to other metabolomics/proteomics/genomics data 
analysis studies. Furthermore, metabolites selected in this 
process may shed lights on the pathways and mechanisms 
underpinning pancreatic cancer onset and/or development. 
The major limitation of this study was the lack of an 
external validation cohort of PDAC patients, which would 
let to corroborate or disprove the performance of MRS we 
achieved using the development cohort of 27 patients. In 
conclusion the implementation of our MRS formula may 
help prioritize the use of available resources for targeting 
aggressive preventive and treatment strategies in a subset 
of very high-risk individuals.
MATERIALS AND METHODS
Study population and inclusion criteria
Forty patients with pancreatic adenocarcinoma were 
consecutively recruited at the Scientific Institute “Casa 
Sollievo della Sofferenza” Hospital in San Giovanni 
Rotondo (Apulia, Italy) from May to November 2012 for 
a serum blood sample collection. All patients signed an 
informed consent approved by the local Ethics Committee. 
The consent included collection of serum sample and 
clinical patient’s features. After excluding patients 
a) who had missing data for one or more baseline clinical 
features (n = 10) and b) whose information on vital status 
at follow-up was not available (n = 3), 27 patients with 
pancreatic adenocarcinoma (67.5% of the initial cohort) 
constituted the eligible sample for the present analysis. PC 
patients’ clinical characteristics evaluated at baseline were 
reported in Table 1.
Random survival forest analysis
This appealing method is widely used to identify, 
among all available covariates (i.e., all metabolites), the 
ones which were most associated to a specific dependent 
variable of interest (i.e. one-year mortality risk). This 
method is also known to provide extremely robust results, 
especially in context of high dimensional dataset. To our 
purpose, we built 100,000 survival trees. The training set 
used to grow each tree is a 0.632+ bootstrap resample 
of the observations [28]. Trees were allowed to grow to 
their full size without pruning. The best split at each node 
of the tree included into the forest was selected from a 
random subset of covariates. At each node, the split which 
maximizes the log-rank score is chosen. The left-out (i.e. 
‘‘out of bag’’) observations were then used to obtain the 
classification error of the considered tree. The Random 
Survival Forest (RFS) goodness of fit was assessed 
averaging the individual tree classification errors. One of 
the most relevant strength of RSF analysis is its capability 
to impute missing data. Prior to splitting a node, missing 
data for a variable is imputed by randomly drawing values 
from non-missing in-bag data. Imputed data is however 
not used to calculate the split-statistic which uses non-
missing data only. Following a node split, imputed data 
are reset to missing and the process is repeated until 
terminal nodes are reached. Missing data in terminal 
nodes are imputed using OOB non-missing terminal 
node data. Furthermore, the RSF framework estimates 
the importance of each covariate achieved to discriminate 
the dependent variable by looking at how much the 
classification error increases when out of bag data for that 
variable are permuted, while all others are left unchanged. 
The variables’ importance is ranked by assigning to 
each covariate a score based on the ability to predict 
correctly the dependent variable according to the increase 
of classification error when values of that covariate in a 
node were randomly permuted. Furthermore, the relative 
variables’ importance is defined, for each covariate, as the 
ratio of the score assigned to the specific covariate and 
the score assigned to the first ranked covariate (which, by 
definition, is the most important one). The Breiman-Cutler 
measure is used. This measure is constructed by permuting 
the values of each variable of the test set, recording the 
prediction and comparing it with the un-permuted test set 
prediction of the variable. Therefore, it is the increase in 
the percentage of times a test set is misclassified when the 
variable is permuted.
Statistical analysis
Clinical patients’ characteristics and metabolites 
concentration levels were reported as medians (along with 
lower-upper quartiles) or frequencies and percentages for 
continuous and categorical variables, respectively. The 
overall mortality rate was calculated as the number of 
death events per 100 person-years. 
Association between clinical variables and 
metabolites concentration levels were assessed using 
Mann-Whitney U test (or Kruskal-Wallis when appropriate) 
or Spearman correlation coefficient for categorical and 
continuous clinical variables, respectively.
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Table 1: Baseline clinical-pathological characteristics of all 27 patients with pancreatic cancer
Age at diagnosis (yrs), median (Q1–Q3) 66 (56–76)
Gender, n males (%) 13 (48.15)
BMI (kg/m2), median (Q1–Q3) 24.8 (22.96–29.23)
Waist (cm), median (Q1–Q3) 101 (88–109)
Presence of diabete, n (%) 10 (37.04)
Presence of hypertension, n (%) 9 (33.33)
Glycemia (mg/dl), median (Q1–Q3) 123 (97–145)
Triglycerides (mg/dl), median (Q1–Q3) 119.5 (83.5–304)
Total cholesterol (mg/dl), median (Q1–Q3) 150.5 (127.5–215.5)
Lactate dehydrogenase (UI/l), median (Q1–Q3) 348 (260–372)
Smoking habits, n (%)
 Yes 6 (22.22)
 No 14 (51.85)
 Ex 7 (25.93)
Alcohol consumption, n (%)
 No drinker 8 (30.77)
 Occasional drinker 10 (38.46)
 Moderate drinker 5 (19.23)
 Heavy drinker 3 (11.54)
 Missing information 1
Coffee consumption, n (%)
 No 5 (20)
 Yes 20 (80)
 Missing information 2
Nr. drinked cups of coffee/day, median (Q1–Q3) 2 (1–4)
Presence of (any) familiarity, n (%) 11 (40.74)
CA 19-9 (U/ml), median (Q1–Q3) 1839.5 (860–3398)
Jaundice, n (%)
 No 9 (39.13)
 Yes 14 (60.87)
 Missing information 4
Pain, n (%)
 No 7 (28)
 Yes 18 (72)
 Missing information 2
Weight loss, n (%)
 No 3 (18.75)
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 Yes 13 (81.25)
 Missing information 11
Surgical resection, n (%) 7 (25.93)
Tumour localization, n (%)
 Body/tail 5 (18.52)
 Head 22 (81.48)
T: Tumour size, n (%)
 Tx 4
 T1 1 (4.35)
 T2 2 (8.7)
 T3 11 (47.83)
 T4 9 (39.13)
N: regional lymph nodes, n (%)
 Nx 9
 N0 4 (22.22)
 N1 13 (72.22)
 N2 1 (5.56)
M: distant metastasis, n (%)
 Mx 7
 M0 10 (50)
 M1 10 (50)
Margins of resection, n (%)
 Rx 1
 R0 4 (15.38)
 R1 2 (7.69)
 R2 20 (76.92)
Presence of vascular invasion, n (%) 6 (22.22)
Presence of chemotherapy, n (%) 13 (48.15)
Disease duration (yrs)*, median (Q1–Q3) 0.45 (0.1–1.11)
Time from diagnosis (yrs)**, median (Q1–Q3) 0.1 (0.06–0.45)
Overall follow-up time (yrs), median (Q1–Q3) 0.34 (0.16–0.56)
Mortality rate overall, ev/py (ir%)^ 18/45 (39.7)
Mortality rate at one-year, ev/py (ir%)^ 18/41 (43.5)
*Time from symptoms to blood collection; **Time from diagnosis to blood collection; ^events/person-years, incidence rate 
per 100 person-years; Q1–Q3: first-third quartiles.
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The overall survival was defined as the time between 
baseline and event (i.e. death) dates; for subjects who did 
not experience the event, survival time was censored at the 
time of the last available follow-up information.
Disease duration was defined as the time between 
the date of diagnosis (which precedes the baseline) and 
the baseline date (i.e. the date of serum blood collection).
Time-to-death analyses were performed using 
Weibull survival regression models, and risks were 
reported as hazard ratios (HR) along with their 95% 
 confidence intervals (95% CI). For metabolite 
concentrations, HR were reported for each unitary increase 
of their standard deviation (SD). The appropriateness of 
the Weibull parameterization assumption for the baseline 
hazard was graphically ascertained, plotting the natural 
logarithm of the Kaplan-Meier survival estimate (which 
their values were reverted and logarithm transformed as 
well) against the logarithm of follow-up time. To build 
a Metabolites Risk Score (MRS) which best predicted 
patient’s one-year mortality risk and comprised a 
combination of the highest associated metabolites (i.e. 
predictors), we followed a three-step process: 
Step 1– A Random Survival Forest (RSF) analysis 
[29] [see Random Survival Forest analysis section] 
was performed using metabolites concentration levels 
as continuous splitting variables for the building of 
the forest. All missing values were internally imputed 
by RSF for all covariates as long as their missing rate 
was lower than 25%. When the missing rate is higher 
than 25%, covariates were excluded from any further 
statistical analysis [30].
Step 2 – From RSF variable importance, we selected 
“the most important” metabolites which achieved at least 
20% of relative variable importance. To estimate the 
proper functional relationship between such predictors 
and one-year mortality risk, all the selected metabolites 
were included as covariates into a Weibull survival 
regression and, following a stepwise variable selection 
criterion, we identified the strongest predictors which 
were linearly associated to one-year mortality risk 
(significance level for entry into the model: p = 0.10, 
significance level for staying into the model: p = 0.05). 
The overall models’ goodness of fit was evaluated by the 
Akaike’s information criterion (AIC). At each iteration 
step of the stepwise procedure, all predictors which 
minimize AIC were consecutively included into the 
model, after 10,000 bootstrap resamplings. To provide 
more robustness of the association between the effect of 
stepwise-selected metabolites and one-year mortality risk, 
we further evaluated possible non-linear relationship, 
including metabolites as non-linear trend components 
into two-order fractional polynomial models [31]. 
Furthermore, we checked possible interactions between 
selected metabolites using RECursive Partitioning and 
AMalgamation (RECPAM) method [17, 32].
Step 3 – We finally used the regression coefficients 
estimates from the final multivariable Weibull survival 
model as weights to build the MRS. The “stability” 
of these weights was assessed performing 10,000 
bootstrap resamplings where, at each iteration step, a 
multivariable Weibull model was run on the bootstrapped 
sample and the estimates of regression coefficients were 
stored. Thereafter, the empirical distribution of each 
weight was determined along with the corresponding 
distribution-based 95%CI. Therefore, assuming that the 
survival time is a random variable which follows a Weibull 
distribution with scale and shape parameters of λ and γ 
respectively, the patient’s baseline survivor function S0 (t) 
is characterized by the following formula: S0 (t) = exp 
{−(λt)γ}, where t is any non-negative specific survival time 
point. Following the assumption of proportional hazards 
(i.e., the effect of the covariates increase or decrease 
the hazard by a proportionate amount at all durations) 
and having considered we want to make a mortality risk 
prediction at one-year (i.e., t = 1), we built the MRS as 
follows:
^MRS = 1 −S0 (t)
e∑
p
i = 1  βi 
(Xi−Xi) = 1 − exp{−λγ}e∑
p
i = 1 βi (Xi−Xi)
^ ^ ^
Where λ^ = 1/exp (β^0) and γ^ are the Weibull scale 
and shape parameters estimated from the empty Weibull 
model (without covariates), respectively, and β^0 is the 
model’s intercept and β^ i is the i-th regression coefficient 
for the i-th Xi metabolite (estimated from the multivariable 
Weibull model), which values were centered around their 
sample mean. The obtained MRS ranged from 0 (lowest 
mortality risk within one year of follow-up) to 1 (highest 
mortality risk within one year of follow-up). Furthermore, 
RECPAM method was used to identify optimal cut-offs 
for MRS which defined patients’ subgroups at different 
mortality risk.
Models’ discrimination, i.e. the ability to distinguish 
subjects who will develop an event from those who will 
not, was assessed by computing the modified C-statistic for 
censored survival data [33], using predicted probabilities 
at one-year.
All statistical analyses were performed using 
SAS Release 9.3 (SAS Institute, Cary, NC, USA) and 
R software (ver. 2.15, packages: ‘randomforestSRC’, 
‘survival’, ‘MASS’, ‘mpf’, ‘boot’).
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